Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemzoparlimab dose-escalation and expansion with azacitidine and/or venetoclax in AML or MDS
jRCT2051210150Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of lemzoparlimab, venetoclax and azacitidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (7 arms), sponsored by AbbVie Inc. Primary endpoint: Dose Limiting Toxicities. Started Apr 2022; status: active, not recruiting.
02
Drugs
lemzoparlimabvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2051210150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210150.